Analgesic use and the risk for progression of chronic kidney disease

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 7, 2010, Pages 745-751

  Kuo, Hsin Wei ^a,b   Tsai, Shang Shyue ^c   Tiao, Mao Meng ^d   Liu, Yi Chun ^b   Lee, I Ming ^a   Yang, Chun Yuh ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b YUAN'S GENERAL HOSPITAL   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Analgesics; Chronic kidney disease; Cyclooxygenase 2 inhibitors; End stage renal disease; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB; ANALGESIC AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CHILD; CONTROLLED STUDY; DATA BASE; DISEASE COURSE; FEMALE; HEALTH SERVICE; HUMAN; INFANT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; NATIONAL HEALTH INSURANCE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME; COHORT ANALYSIS; DOSE RESPONSE; EPIDEMIOLOGY; FACTUAL DATABASE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; TAIWAN; YOUNG ADULT;

ACETAMINOPHEN; ADOLESCENT; ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; TAIWAN; YOUNG ADULT;

EID: 77955622226     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1962     Document Type: Article

References (29)

1. Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis 2007; 49: 46-55.
2. Grimlund K. Phenacetin and renal damage at a Swedish factory. Acta Med Scand Suppl 1963; 405: 1-26.
3. Lorz C, Justo P, Sanz A, Subirá D, Egido J, Ortiz A. Paracetamol-induced renal tubular injury: a role for ER stress. J Am Soc Nephrol 2004; 15: 380-389.
4. Emeigh Hart SG, Wyand DS, Khairallah EA, Cohen SD. Acetaminophen nephrotoxicity in the CD-1 mouse. II. Protection by probenecid and AT-125 without diminution of renal covalent binding. Toxicol Appl Pharmacol 1996; 136: 161-169.
5. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol 1995; 6: 48-53.
6. Pérez Gutthann S, García Rodríguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996; 156: 2433-2439.
7. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45: 531-539.
8. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990; 30: 717-723.
9. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165-172.
10. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994; 331: 1675-1679.
11. Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983; 143: 1687-1693.
12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-1528.
13. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
14. ATC Classification and DDD Assignment. WHO Collaborating Centre for Drugs Statistics Methodology, Oslo, 2002.
15. Mantel N. Chi-square tests with one degree of freedom; Extensions of the Mantel-Hanszel procedure. J Am Stat Assoc 1963; 58: 690-700.
16. Spühler O, Zollinger HU. Die chronisch-interstitielle Nephritis. Z Klin Med 1953; 151: 1-50.
17. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989; 9: 403-412. (Pubitemid 19245927)
18. Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995; 48: 1912-1919 .
19. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345: 1801-1808.
20. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007; 120: 280.e1-7.
21. Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM. Analgesic use and renal function in men. JAMA 2001; 286: 315-321.
22. Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis 2003; 42: 234-244.
23. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164: 1519-1524.
24. Agodoa LY, Francis ME, Eggers PW. Association of analgesic use with prevalence of albuminuria and reduced GFR in US adults. Am J Kidney Dis 2008; 51: 573-583.
25. Granese J, Brightbill K, Osborne P, Cox CE, Gaber LW. Analgesic nephropathy selectively affecting a unilateral non-functioning hypoplastic kidney. Clin Nephrol 2007; 68: 115-120.
26. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619-1632.
27. Hermann M, Shaw S, Kiss E, et al. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005; 45: 193-197.
28. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-496.
29. Chang IJ, Harris RC. Are all COX-2 inhibitors created equal? Hypertension 2005; 45: 178-180.